The Future of Nuclear Medicine, Molecular Imaging, and Theranostics.

### Wolfgang A. Weber and Johannes Czernin Scientific discoveries published in The Journal of Nuclear Medicine over the past 60 years have shaped the practice of medicine and form the foundation for the future of nuclear medicine, molecular imaging, and theranostics. Nuclear medicine now provides

[1]  C. Koumenis,et al.  Precision Cardio-Oncology , 2019, The Journal of Nuclear Medicine.

[2]  E. Winer,et al.  18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials , 2016, Clinical Cancer Research.

[3]  J. Thackeray.  Imaging the Molecular Footprints of the Heart–Brain Axis in Cardiovascular Disease , 2019, The Journal of Nuclear Medicine.

[4]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[5]  M. Koole,et al.  Targeted Alpha Therapy: a critical review of translational dosimetry research with emphasis on Actinium-225. , 2020, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[6]  B. McNeil,et al.  Radiotheranostics: a roadmap for future development. , 2020, The Lancet. Oncology.

[7]  Barbara E Hertz,et al.  A tribute to Dr. Saul Hertz: The discovery of the medical uses of radioiodine , 2019, World journal of nuclear medicine.

[8]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. , 2017, European urology.

[9]  Wolfgang A. Weber,et al.  Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine , 2019, The Journal of Nuclear Medicine.

[10]  F. Bengel,et al.  The Changing Face of Nuclear Cardiology: Guiding Cardiovascular Care Toward Molecular Medicine , 2020, The Journal of Nuclear Medicine.

[11]  J. Trojanowski,et al.  Spreading of pathology in neurodegenerative diseases: a focus on human studies , 2015, Nature Reviews Neuroscience.

[12]  J. Links,et al.  Detection and comparison of patterns in images. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  W. Moses,et al.  Total-Body PET: Maximizing Sensitivity to Create New Opportunities for Clinical Research and Patient Care , 2018, The Journal of Nuclear Medicine.

[14]  S. Hertz,et al.  RADIOACTIVE IODINE AS AN INDICATOR IN THYROID PHYSIOLOGY. IV. THE METABOLISM OF IODINE IN GRAVES' DISEASE. , 1942, The Journal of clinical investigation.

[15]  E. Krenning,et al.  Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer. , 2016, Seminars in nuclear medicine.

[16]  D. Mankoff,et al.  Molecular Imaging Biomarkers for Oncology Clinical Trials , 2014, The Journal of Nuclear Medicine.

[17]  W. Oyen,et al.  PET/CT: panacea, redundancy, or something in between? , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  G. Corrado,et al.  End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography , 2019, Nature Medicine.

[19]  B. Taylor,et al.  EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. , 2018, Cancer discovery.

[20]  Vasilis Ntziachristos,et al.  Optoacoustic mesoscopy for biomedicine , 2019, Nature Biomedical Engineering.

[21]  G. Segall.  Looking to the Future: The ABNM in the Next 10 Years. , 2016, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  A. Masri,et al.  Molecular Imaging of Cardiac Amyloidosis , 2020, The Journal of Nuclear Medicine.

[23]  Jason S. Lewis,et al.  Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer , 2019, Clinical Cancer Research.

[24]  Stephanie L. Lee.  Radioactive iodine therapy , 2012, Current opinion in endocrinology, diabetes, and obesity.

[25]  Jason S. Lewis,et al.  Pretargeted Immuno-PET of Pancreatic Cancer: Overcoming Circulating Antigen and Internalized Antibody to Reduce Radiation Doses , 2016, The Journal of Nuclear Medicine.

[26]  Maurizio Conti,et al.  Benefit of Improved Performance with State-of-the Art Digital PET/CT for Lesion Detection in Oncology , 2020, The Journal of Nuclear Medicine.

[27]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[28]  Jason S. Lewis,et al.  Radiopharmaceutical Chemistry , 2019, Springer International Publishing.

[29]  J. Seibyl,et al.  The role of positron emission tomography imaging in understanding Alzheimer’s disease , 2015, Expert review of neurotherapeutics.

[30]  Pengcheng Hu,et al.  First Human Imaging Studies with the EXPLORER Total-Body PET Scanner* , 2019, The Journal of Nuclear Medicine.

[31]  H N Wagner,et al.  Assessment of pulmonary lesions with 18F-fluorodeoxyglucose positron imaging using coincidence mode gamma cameras. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  J. Berlin,et al.  Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors , 2017, The New England journal of medicine.

[33]  H Fujita,et al.  Application of artificial neural network to computer-aided diagnosis of coronary artery disease in myocardial SPECT bull's-eye images. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  E. D. de Vries,et al.  Molecular imaging biomarkers for immune checkpoint inhibitor therapy , 2020, Theranostics.

[35]  John Maher,et al.  New Developments in Imaging Cell-Based Therapy , 2019, The Journal of Nuclear Medicine.

[36]  A. Nunn,et al.  The Cost of Developing Imaging Agents for Routine Clinical Use , 2006, Investigative radiology.

[37]  W. Miller,et al.  A review of cancer immunotherapy: from the past, to the present, to the future. , 2019, Current oncology.

[38]  S. Mirzadeh,et al.  Automated cassette-based production of high specific activity [203/212Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer. , 2017, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[39]  M. Pomper,et al.  Imaging of Prostate-Specific Membrane Antigen with Small-Molecule PET Radiotracers: From the Bench to Advanced Clinical Applications. , 2019, Annual review of medicine.

[40]  F. Mottaghy,et al.  225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[41]  C. Rudin,et al.  Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer. , 2017, Cancer research.

[42]  V. Beylergil,et al.  Roundtable on the Future of Nuclear Medicine Training , 2015, The Journal of Nuclear Medicine.

[43]  J. Kippenhan,et al.  Evaluation of a neural-network classifier for PET scans of normal and Alzheimer's disease subjects. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[44]  R. Scott,et al.  Artificial intelligence: its use in medical diagnosis. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[45]  Frederik L. Giesel,et al.  68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer , 2019, The Journal of Nuclear Medicine.

[46]  W. Steenbergen,et al.  Recent Development of Technology and Application of Photoacoustic Molecular Imaging Toward Clinical Translation , 2018, The Journal of Nuclear Medicine.

[47]  S. M. Seidlin,et al.  Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid. , 1946, Journal of the American Medical Association.

[48]  J. Czernin.  Reply: Roundtable on the Future of Nuclear Medicine Training , 2015, The Journal of Nuclear Medicine.

[49]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[50]  M. Lassmann,et al.  The Relevance of Dosimetry in Precision Medicine , 2018, The Journal of Nuclear Medicine.